Trial Profile
A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ANGEL
- Sponsors Elevar Therapeutics; LSK Biopharma
- 10 Oct 2020 This trial has been completed in Germany, Poland and France.
- 22 Jun 2020 Planned End Date changed from 31 Mar 2019 to 31 Jul 2020.
- 09 Mar 2020 According to an Elevar Therapeutics media release, the company is in discussions with the FDA to receive advice on regulatory submissions for monotherapy gastric cancer treatment.